Related Experiment Video
Updated: May 23, 2026

Minimally Invasive Muscle Embedding (MIME) - A Novel Experimental Technique to Facilitate Donor-Cell-Mediated Myogenesis
Published on: August 24, 2017
Biological approaches to improve skeletal muscle healing after injury and disease
Burhan Gharaibeh1, Yuri Chun-Lansinger, Tanya Hagen
1Stem Cell Research Center, Department of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania 15219, USA.
Abstract:
Skeletal muscle injury and repair are complex processes, including well-coordinated steps of degeneration, inflammation, regeneration, and fibrosis. We have reviewed the recent literature including studies by our group that describe how to modulate the processes of skeletal muscle repair and regeneration. Antiinflammatory drugs that target cyclooxygenase-2 were found to hamper the skeletal muscle repair process. Muscle regeneration phase can be aided by growth factors, including insulin-like growth factor-1 and nerve growth factor, but these factors are typically short-lived, and thus more effective methods of delivery are needed. Skeletal muscle damage caused by traumatic injury or genetic diseases can benefit from cell therapy; however, the majority of transplanted muscle cells (myoblasts) are unable to survive the immune response and hypoxic conditions. Our group has isolated neonatal skeletal muscle derived stem cells (MDSCs) that appear to repair muscle tissue in a more effective manner than myoblasts, most likely due to their better resistance to oxidative stress. Enhancing antioxidant levels of MDSCs led to improved regenerative potential. It is becoming increasingly clear that stem cells tissue repair by direct differentiation and paracrine effects leading to neovascularization of injured site and chemoattraction of host cells. The factors invoked in paracrine action are still under investigation. Our group has found that angiotensin II receptor blocker (losartan) significantly reduces fibrotic tissue formation and improves repair of murine injured muscle. Based on these data, we have conducted a case study on two hamstring injury patients and found that losartan treatment was well tolerated and possibly improved recovery time. We believe this medication holds great promise to optimize muscle repair in humans.
Insights
Investigating skeletal muscle repair revealed anti-inflammatory drugs hinder healing. However, stem cell therapy and losartan show promise for enhancing muscle regeneration and reducing fibrosis.
Area of Science:
- Muscle physiology and regenerative medicine.
- Cellular and molecular mechanisms of tissue repair.
Background:
- Skeletal muscle repair involves degeneration, inflammation, regeneration, and fibrosis.
- Current therapies like anti-inflammatory drugs and growth factors have limitations.
- Cell therapy using myoblasts faces challenges with survival and immune response.
Purpose of the Study:
- To review and present novel strategies for modulating skeletal muscle repair and regeneration.
- To evaluate the efficacy of neonatal skeletal muscle-derived stem cells (MDSCs) and losartan in muscle repair.
Main Methods:
- Literature review of skeletal muscle repair mechanisms.
- Isolation and characterization of neonatal skeletal muscle-derived stem cells (MDSCs).
- Preclinical studies in murine models and a case study in human patients.
Main Results:
- Anti-inflammatory drugs targeting cyclooxygenase-2 impede muscle repair.
- MDSCs demonstrate superior repair capabilities compared to myoblasts, enhanced by antioxidants.
- Losartan significantly reduced fibrosis and improved muscle repair in mice.
- Case study suggests losartan is well-tolerated and may accelerate recovery in hamstring injuries.
Conclusions:
- Neonatal skeletal muscle-derived stem cells offer a promising therapeutic avenue for muscle regeneration.
- Losartan demonstrates potential in reducing fibrosis and optimizing skeletal muscle repair.
- Further research is warranted to explore the therapeutic applications of MDSCs and losartan in human muscle injuries.

